Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

63
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
63
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

110
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
110
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

96
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
96
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

603
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
603

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Images: Multicentric reticulohistiocytosis.

ACR open rheumatologyยท2023
See all related articles

Related Experiment Video

Updated: Nov 14, 2025

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis
04:01

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis

Published on: June 14, 2024

1.2K

Challenges in Treating Statin-Associated Necrotizing Myopathy.

Patrick Webster1, Nicholas Wiemer1, Abdalhamid Al Harash2

  • 1Department of Internal Medicine, Allegheny Health Network, Pittsburgh, USA.

Case Reports in Rheumatology
|March 12, 2021
PubMed
Summary

Statin-associated autoimmune myopathy, an immune condition, causes progressive muscle weakness. Treatment often requires immunosuppressants and IV immunoglobulin, showing promise especially in diabetic patients.

More Related Videos

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

9.2K

Related Experiment Videos

Last Updated: Nov 14, 2025

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis
04:01

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis

Published on: June 14, 2024

1.2K
Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

9.2K

Area of Science:

  • Rheumatology
  • Neurology
  • Clinical Pharmacology

Background:

  • Statin therapy, widely used for hyperlipidemia, can rarely trigger immune-mediated necrotizing myopathy.
  • This condition involves autoantibodies against HMG-CoA reductase, leading to persistent muscle weakness and elevated creatine kinase (CK) levels.

Observation:

  • This case series details the clinical and pathological features of statin-associated autoimmune myopathy.
  • Presentations varied, from mild symptoms with high CK to severe weakness, including dysphagia.
  • Patients often required multiple immunosuppressants and intravenous immunoglobulin (IVIG) for disease management.

Findings:

  • Progressive symmetric proximal weakness, unresponsive to statin cessation, is a hallmark.
  • Markedly elevated CK levels are consistently observed.
  • Intravenous immunoglobulin (IVIG) demonstrated significant improvement in several diabetic patients.

Implications:

  • Highlights diagnostic challenges and treatment complexities for statin-associated autoimmune myopathy.
  • Suggests IVIG as a potentially effective therapeutic option, particularly for diabetic individuals.
  • Emphasizes the need for further research, including randomized controlled trials, to establish optimal treatment protocols.